86 related articles for article (PubMed ID: 21256247)
1. An evaluation of a Simon 2-Stage phase II clinical trial design incorporating toxicity monitoring.
Ray HE; Rai SN
Contemp Clin Trials; 2011 May; 32(3):428-36. PubMed ID: 21256247
[TBL] [Abstract][Full Text] [Related]
2. Operating characteristics of a Simon two-stage phase II clinical trial design incorporating continuous toxicity monitoring.
Ray HE; Rai SN
Pharm Stat; 2012; 11(2):170-6. PubMed ID: 22232063
[TBL] [Abstract][Full Text] [Related]
3. A strategy for dose-finding and safety monitoring based on efficacy and adverse outcomes in phase I/II clinical trials.
Thall PF; Russell KE
Biometrics; 1998 Mar; 54(1):251-64. PubMed ID: 9544520
[TBL] [Abstract][Full Text] [Related]
4. Continuous toxicity monitoring in phase II trials in oncology.
Ivanova A; Qaqish BF; Schell MJ
Biometrics; 2005 Jun; 61(2):540-5. PubMed ID: 16011702
[TBL] [Abstract][Full Text] [Related]
5. Optimal and minimax three-stage designs for phase II oncology clinical trials.
Chen K; Shan M
Contemp Clin Trials; 2008 Jan; 29(1):32-41. PubMed ID: 17544337
[TBL] [Abstract][Full Text] [Related]
6. An extension of the single threshold design for monitoring efficacy and safety in phase II clinical trials.
Brutti P; Gubbiotti S; Sambucini V
Stat Med; 2011 Jun; 30(14):1648-64. PubMed ID: 21520453
[TBL] [Abstract][Full Text] [Related]
7. Targeting population entering phase III trials: a new stratified adaptive phase II design.
Tournoux-Facon C; De Rycke Y; Tubert-Bitter P
Stat Med; 2011 Apr; 30(8):801-11. PubMed ID: 21432875
[TBL] [Abstract][Full Text] [Related]
8. Toxicity-evaluation designs for phase I/II cancer immunotherapy trials.
Messer K; Natarajan L; Ball ED; Lane TA
Stat Med; 2010 Mar; 29(7-8):712-20. PubMed ID: 20213706
[TBL] [Abstract][Full Text] [Related]
9. Flexible bivariate phase II clinical trial design incorporating toxicity and response on different schedules.
Ray HE; Rai SN
Stat Med; 2013 Feb; 32(3):470-85. PubMed ID: 23147373
[TBL] [Abstract][Full Text] [Related]
10. Optimal two-stage designs allowing flexibility in number of subjects for phase II clinical trials.
Masaki N; Koyama T; Yoshimura I; Hamada C
J Biopharm Stat; 2009 Jul; 19(4):721-31. PubMed ID: 20183436
[TBL] [Abstract][Full Text] [Related]
11. Alternative designs of phase II trials considering response and toxicity.
Jin H
Contemp Clin Trials; 2007 Jul; 28(4):525-31. PubMed ID: 17428744
[TBL] [Abstract][Full Text] [Related]
12. Incorporating toxicity considerations into the design of two-stage phase II clinical trials.
Bryant J; Day R
Biometrics; 1995 Dec; 51(4):1372-83. PubMed ID: 8589229
[TBL] [Abstract][Full Text] [Related]
13. An adjustment for patient heterogeneity in the design of two-stage phase II trials.
Sposto R; Gaynon PS
Stat Med; 2009 Sep; 28(20):2566-79. PubMed ID: 19521973
[TBL] [Abstract][Full Text] [Related]
14. Adaptive dose selection using efficacy-toxicity trade-offs: illustrations and practical considerations.
Thall PF; Cook JD; Estey EH
J Biopharm Stat; 2006; 16(5):623-38. PubMed ID: 17037262
[TBL] [Abstract][Full Text] [Related]
15. Methods of joint evaluation of efficacy and toxicity in phase II clinical trials.
Tournoux C; De Rycke Y; Médioni J; Asselain B
Contemp Clin Trials; 2007 Jul; 28(4):514-24. PubMed ID: 17331808
[TBL] [Abstract][Full Text] [Related]
16. Effect of a misspecification of response rates on type I and type II errors, in a phase II Simon design.
Baey C; Le Deley MC
Eur J Cancer; 2011 Jul; 47(11):1647-52. PubMed ID: 21493059
[TBL] [Abstract][Full Text] [Related]
17. Optimal continuous sequential boundaries for monitoring toxicity in clinical trials: a restricted search algorithm.
Goldman AI; Hannan PJ
Stat Med; 2001 Jun; 20(11):1575-89. PubMed ID: 11391689
[TBL] [Abstract][Full Text] [Related]
18. Phase I (or phase II) dose-ranging clinical trials: proposal of a two-stage Bayesian design.
Zohar S; Chevret S
J Biopharm Stat; 2003 Feb; 13(1):87-101. PubMed ID: 12635905
[TBL] [Abstract][Full Text] [Related]
19. Seamless Phase II/III combination study through response adaptive randomization.
Wang L; Cui L
J Biopharm Stat; 2007; 17(6):1177-87. PubMed ID: 18027224
[TBL] [Abstract][Full Text] [Related]
20. A parallel phase I/II clinical trial design for combination therapies.
Huang X; Biswas S; Oki Y; Issa JP; Berry DA
Biometrics; 2007 Jun; 63(2):429-36. PubMed ID: 17688495
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]